Visugromab RDE (recommended dose for expansion)

Phase 2

Visugromab RDE (recommended dose for expansion) is one of 5 therapeutic programs targeting Metastatic Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Hepatocellular CarcinomaRecruiting

Metastatic Hepatocellular CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Metastatic Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

1 2

Lenvima

Eisai

Phase 2

1 3

Beyfortus

BeiGene

Phase 1

1 4

Avastin

BBio-Thera Solutions

Phase 1

1 5

Visugromab RDE (recommended dose for expansion)

CCatalYm GmbH

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 2Recruiting

Metastatic Hepatocellular Carcinoma

NCT07219459

Clinical

Trials by Indication[1]

Metastatic Hepatocellular Carcinoma1 trial

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)

Recruiting·CCatalYm GmbH·Phase 2·NCT07219459·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Visugromab RDE (recommended dose for expansion). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Visugromab RDE (recommended dose for expansion). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — CatalYm GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CCatalYm GmbH

Visugromab RDE (recommended dose for expansion)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Metastatic Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News